Santarus, (FRA:TW4A) 14-Day RSI : N/A (As of May. 08, 2024)

View and export this data going back to . Start your Free Trial

What is Santarus, 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-05-08), Santarus,'s 14-Day RSI is N/A.

The industry rank for Santarus,'s 14-Day RSI or its related term are showing as below:

FRA:TW4A's 14-Day RSI is not ranked ^*
in the Biotechnology industry.
Industry Median: 49.075
* Ranked among companies with meaningful 14-Day RSI only.

Competitive Comparison of Santarus,'s 14-Day RSI

For the Biotechnology subindustry, Santarus,'s 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Santarus,'s 14-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Santarus,'s 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Santarus,'s 14-Day RSI falls into.

Santarus, (FRA:TW4A) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI

100

–

[ 100

( 1 + Average Gain

Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Santarus, (FRA:TW4A) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.

Santarus, 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Santarus,'s 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.

Santarus, (FRA:TW4A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Santarus, Inc. (FRA:TW4A) » Definitions » 14-Day RSI

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.santarus.com

Santarus, Inc. was incorporated on December 6, 1996 as a California corporation and did not commence significant business activities until late 1998. On July 9, 2002, the Company reincorporated in the State of Delaware. The Company is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. It sells brand prescription products primarily to pharmaceutical wholesalers, who in turn seek to distribute the products to retail pharmacies, mail order pharmacies, hospitals and other institutional customers. The Company's current commercial efforts are focused on five products: UCERIS, extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis and ZEGERID for the treatment of certain upper gastrointestinal disorders are promoted to gastroenterologists; GLUMETZA and CYCLOSET tablets, which are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes; and FENOGLIDE tablets, which is indicated as an adjunct to diet to reduce high cholesterol. The pipeline products include the investigational drug RUCONEST for treatment of acute attacks of hereditary angioedema.

Santarus, (FRA:TW4A) Headlines

No Headlines